A Phase 2a, Randomized, Double-blind, Placebo-controlled Study To Evaluate The Efficacy, Safety, Tolerability And Pharmacokinetics Of Pf-06687234 As Add-on Therapy To Infliximab In Active Ulcerative Colitis Subjects Who Are Not In Remission (Build Uc)
Phase of Trial: Phase II
Latest Information Update: 15 Dec 2017
At a glance
- Drugs F8 IL10 (Primary) ; Infliximab
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Pfizer
- 11 Dec 2017 Planned End Date changed from 25 Feb 2020 to 1 Feb 2020.
- 11 Dec 2017 Planned primary completion date changed from 25 Feb 2020 to 1 Feb 2020.
- 13 Nov 2017 Planned initiation date changed from 31 Oct 2017 to 17 Nov 2017.